LBP and metabolic dysfunction-associated steatotic liver disease: YCHD combined with probiotics significantly ameliorates symptoms of non-alcoholic fatty liver disease, reduces levels of blood lipids and liver enzymes, prevents hepatocyte destruction, and notably decreases levels of lipopolysaccharide-binding protein (LBP), total bile acid (TBA) and TNF-α.